FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ngton, D.C. 20549	OMB APPROVAL

	OMB Number:	3235-0287
ı	Estimated average bur	den
-	L	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Unum Therapeutics Inc. [UMRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Ferrante Karen Jean</u>					Onam Therapeutics Inc. [Ownex]								X Dir	ector		10% O	vner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)								Off bel		ive title	Other (s	specify	
C/O UNUM THERAPEUTICS INC.				107	07/01/2019													
200 CAMBRIDGE PARK DRIVE, SUITE 3100				4 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
				- '	4. II Amendment, Date of Original Filed (Month/Ddy/fedf)								Line)					
(Street)														X Fo	m file	d by One Rep	orting Perso	n
CAMBRIDGE MA 02140													Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)															
		Tal	ble I - Non	-Deriv	/ativ	e Se	curities	Acc	quired, [Disp	osed of	f, or Ber	neficia	lly Own	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,		Code (Instr. 5)				d Secu Bene Own	Securities For Beneficially (D Owned Following (I)		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	mount (A) or (D)		Tran	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
		,	Table II - I (sed of, onvertib			y Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		•	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price Derivat Securit (Instr. 5	ve c	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amoun or Numbe of Shares			ransaction(s) Instr. 4)		
Stock Option (Right to Buy)	\$2.41	07/01/2019			A		6,199 ⁽¹⁾		(2)		07/01/2029	Common Stock	6,199	\$1.774	15	6,199	D	

1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

2. This option is fully vested at time of grant.

Remarks:

/s/ Amoli Pandya, as Attorney-07/03/2019 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.